New medicines to deliver a new future for patients and their families by transforming gene regulation in disease were developed by Fulcrum Therapeutics. This company is spinoff of Harvard University. The sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. The Fulcrum product engine is based on the breakthrough biology of gene regulation. It will bring to bear medicines for devastating diseases across multiple therapeutic areas by modulating – or balancing – the expression of the genes known to drive disease.